Skip to main content
Caplight Logo









Fzata, Inc.

Fzata, Inc.

Private
MarylandHealthcare & Life Scienceshttps://www.fzata.com/

Last Round

Grant

Sep 24, 2024

Total Funding Raised

$25M

Company Overview

Fzata, Inc. is a biopharmaceutical company that develops oral live biotherapeutic medicines using its proprietary Bioengineered Probiotic Yeast Medicines (BioPYM™) platform to treat gastrointestinal and gut-brain axis disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

live biotherapeuticoral biologicsdrug delivery systemsynthetic biologygut microbiome therapypill-based medicinetherapeutic proteinsantibody engineeringgastrointestinal disordersneedle-free deliverybiotech platformLBPmicrobiome drugbioengineeringdrug co-development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Fzata, Inc. Comparables

Compare Fzata, Inc. with similar companies based on industry and business-model similarity.

Fzata, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Esperovax
80%
Precigen
78%
Sorriso Therapeutics
76%

Fzata, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 24, 2024
Series AJan 26, 2023
GrantJan 15, 2018

Fzata, Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 24, 2024

    $7M grant awarded by NINDS

  • Mar 28, 2024

    Grew 38% QoQ, from 8 to 11 employees.

Fzata, Inc. Filings

Explore SEC and related filing metadata, where available.

Fzata, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Fzata, Inc.'s valuation, stock price, and market status.

Is Fzata, Inc. a public or private company?

Fzata, Inc. is a private company.

What is the current stock price of Fzata, Inc.?

Fzata, Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is Fzata, Inc. worth (valuation)?

Valuation information for Fzata, Inc. is not publicly available.

Can I buy Fzata, Inc. stock?

Fzata, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Fzata, Inc.'s last funding round?

Fzata, Inc.'s most recent funding round was Grant on September 24, 2024.

Who are the main investors in Fzata, Inc.?

Key investors in Fzata, Inc. include NIH RADx, National Institute of Neurological Disorders and Stroke (NINDS).

Will Fzata, Inc. IPO soon?

No public IPO plans have been announced for Fzata, Inc..

How can I track Fzata, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Fzata, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMaryland
Employee Range9
Year Founded2015
Last FundingSep 24, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?